U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

p53-Mutant Endometrial Endometrioid Adenocarcinoma

MedGen UID:
1792874
•Concept ID:
C5556433
•
Neoplastic Process
Synonym: p53-Mutant Endometrial Endometrioid Carcinoma

Definition

An endometrial endometrioid adenocarcinoma characterized by the presence of p53 gene mutations. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVp53-Mutant Endometrial Endometrioid Adenocarcinoma

Professional guidelines

PubMed

Molecular classification and adjuvant treatment in endometrioid endometrial cancer with microcystic elongated and fragmented (MELF) invasion pattern.
Jia P, Zhang Y
BMC Womens Health 2024 Nov 15;24(1):607. doi: 10.1186/s12905-024-03449-6. PMID: 39548429Free PMC Article
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T
Histopathology 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. PMID: 31846532Free PMC Article
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT
Clin Cancer Res 2016 Aug 15;22(16):4215-24. Epub 2016 Mar 22 doi: 10.1158/1078-0432.CCR-15-2878. PMID: 27006490

Recent clinical studies

Etiology

Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B, Wu J, Sun L, Yang C, Yu H, Hao Q, Wang J, Zhang H
Int J Gynecol Pathol 2024 May 1;43(3):233-241. Epub 2023 Sep 8 doi: 10.1097/PGP.0000000000000980. PMID: 37733028
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, Varricchio S, Casadio P, Inzani F, Seracchioli R, Mollo A, Mascolo M, Zannoni GF
Int J Mol Sci 2022 Oct 2;23(19) doi: 10.3390/ijms231911684. PMID: 36232987Free PMC Article
Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA, Atenafu EG, Singh N, Ghatage P, Clarke BA, Nelson GS, Bernardini MQ, Köbel M
Int J Gynecol Pathol 2021 Mar 1;40(2):116-123. doi: 10.1097/PGP.0000000000000674. PMID: 32265358
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T
Histopathology 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. PMID: 31846532Free PMC Article
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT
Clin Cancer Res 2016 Aug 15;22(16):4215-24. Epub 2016 Mar 22 doi: 10.1158/1078-0432.CCR-15-2878. PMID: 27006490

Diagnosis

The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL, Banet N, Buza N
Pathology 2023 Feb;55(1):8-18. Epub 2022 Nov 23 doi: 10.1016/j.pathol.2022.11.004. PMID: 36503635
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, Varricchio S, Casadio P, Inzani F, Seracchioli R, Mollo A, Mascolo M, Zannoni GF
Int J Mol Sci 2022 Oct 2;23(19) doi: 10.3390/ijms231911684. PMID: 36232987Free PMC Article
Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA, Atenafu EG, Singh N, Ghatage P, Clarke BA, Nelson GS, Bernardini MQ, Köbel M
Int J Gynecol Pathol 2021 Mar 1;40(2):116-123. doi: 10.1097/PGP.0000000000000674. PMID: 32265358
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T
Histopathology 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. PMID: 31846532Free PMC Article
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT
Clin Cancer Res 2016 Aug 15;22(16):4215-24. Epub 2016 Mar 22 doi: 10.1158/1078-0432.CCR-15-2878. PMID: 27006490

Therapy

The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL, Banet N, Buza N
Pathology 2023 Feb;55(1):8-18. Epub 2022 Nov 23 doi: 10.1016/j.pathol.2022.11.004. PMID: 36503635
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T
Histopathology 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. PMID: 31846532Free PMC Article
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT
Clin Cancer Res 2016 Aug 15;22(16):4215-24. Epub 2016 Mar 22 doi: 10.1158/1078-0432.CCR-15-2878. PMID: 27006490

Prognosis

Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B, Wu J, Sun L, Yang C, Yu H, Hao Q, Wang J, Zhang H
Int J Gynecol Pathol 2024 May 1;43(3):233-241. Epub 2023 Sep 8 doi: 10.1097/PGP.0000000000000980. PMID: 37733028
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, Varricchio S, Casadio P, Inzani F, Seracchioli R, Mollo A, Mascolo M, Zannoni GF
Int J Mol Sci 2022 Oct 2;23(19) doi: 10.3390/ijms231911684. PMID: 36232987Free PMC Article
Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA, Atenafu EG, Singh N, Ghatage P, Clarke BA, Nelson GS, Bernardini MQ, Köbel M
Int J Gynecol Pathol 2021 Mar 1;40(2):116-123. doi: 10.1097/PGP.0000000000000674. PMID: 32265358
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T
Histopathology 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. PMID: 31846532Free PMC Article
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT
Clin Cancer Res 2016 Aug 15;22(16):4215-24. Epub 2016 Mar 22 doi: 10.1158/1078-0432.CCR-15-2878. PMID: 27006490

Clinical prediction guides

The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL, Banet N, Buza N
Pathology 2023 Feb;55(1):8-18. Epub 2022 Nov 23 doi: 10.1016/j.pathol.2022.11.004. PMID: 36503635
Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
Zong L, Mo S, Sun Z, Lu Z, Yu S, Chen J, Xiang Y
Mod Pathol 2022 Feb;35(2):266-273. Epub 2021 Sep 7 doi: 10.1038/s41379-021-00901-y. PMID: 34493823
Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA, Atenafu EG, Singh N, Ghatage P, Clarke BA, Nelson GS, Bernardini MQ, Köbel M
Int J Gynecol Pathol 2021 Mar 1;40(2):116-123. doi: 10.1097/PGP.0000000000000674. PMID: 32265358
Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC
Gynecol Oncol 2017 Aug;146(2):327-333. Epub 2017 May 13 doi: 10.1016/j.ygyno.2017.05.014. PMID: 28511869
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T
Mod Pathol 2016 Feb;29(2):174-81. Epub 2016 Jan 8 doi: 10.1038/modpathol.2015.147. PMID: 26743472

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...